Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 19,060 Shares

April 9, 2026 by InsiderTrades.com

Key Points

CEO Chad Robins sold 83,332 shares on April 6 under a pre‑arranged Rule 10b5‑1 plan for about $1.20M, trimming his stake by 3.62% to 2,217,781 shares (≈$31.96M).
Adaptive reported a strong quarter with revenue of $71.68M (up ~51% year‑over‑year) and an EPS of -$0.09 versus -$0.19 expected, a beat that helped push the stock up roughly 8.2%.
Analyst sentiment is broadly positive-to-mixed — a consensus "Moderate Buy" with a $18.25 target and some $21 targets from firms like JPMorgan — while institutional investors have materially increased positions and now own about 99.17% of the stock.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) COO Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $13.56, for a total value of $258,453.60. Following the completion of the sale, the chief operating officer directly owned 438,526 shares in the company, valued at approximately $5,946,412.56. This represents a 4.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

On Wednesday, April 8th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.83, for a total value of $458,855.03.
On Wednesday, April 1st, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.45, for a total value of $275,417.00.
On Monday, March 23rd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.83, for a total value of $263,599.80.
On Friday, March 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.37, for a total value of $254,832.20.
On Wednesday, March 18th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.18, for a total value of $251,210.80.
On Monday, March 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.41, for a total value of $255,594.60.
On Wednesday, March 11th, Julie Rubinstein sold 141,583 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.29, for a total value of $1,881,638.07.
On Friday, March 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $12.96, for a total value of $247,017.60.
On Monday, March 9th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.79, for a total value of $457,617.39.
On Tuesday, March 10th, Julie Rubinstein sold 19,460 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.68, for a total value of $285,672.80.

Adaptive Biotechnologies Stock Up 8.2%

ADPT stock opened at $14.84 on Thursday. The business has a 50 day moving average price of $15.17 and a two-hundred day moving average price of $15.98. The company has a market cap of $2.29 billion, a price-to-earnings ratio of -37.10 and a beta of 2.29. Adaptive Biotechnologies Corporation has a twelve month low of $6.77 and a twelve month high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last posted its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.19) by $0.10. The firm had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The business's revenue was up 51.0% compared to the same quarter last year. During the same period last year, the company earned ($0.23) earnings per share. On average, equities research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ADPT has been the subject of several research analyst reports. TD Cowen reiterated a "buy" rating on shares of Adaptive Biotechnologies in a research note on Friday, February 6th. JPMorgan Chase & Co. lifted their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an "overweight" rating in a research note on Friday, February 6th. Weiss Ratings reissued a "sell (d-)" rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Guggenheim lifted their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a "buy" rating in a report on Monday, January 26th. Finally, Piper Sandler set a $21.00 price target on Adaptive Biotechnologies in a report on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $18.25.

Check Out Our Latest Stock Report on ADPT

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of institutional investors have recently modified their holdings of ADPT. Caitong International Asset Management Co. Ltd acquired a new position in shares of Adaptive Biotechnologies during the 4th quarter worth $28,000. Sound Income Strategies LLC acquired a new position in shares of Adaptive Biotechnologies during the 3rd quarter worth $30,000. EverSource Wealth Advisors LLC grew its position in Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company's stock worth $38,000 after acquiring an additional 1,565 shares during the last quarter. Assetmark Inc. grew its position in Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company's stock worth $49,000 after acquiring an additional 2,708 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new stake in Adaptive Biotechnologies during the 4th quarter worth $51,000. Institutional investors and hedge funds own 99.17% of the company's stock.

Adaptive Biotechnologies News Summary

Here are the key news stories impacting Adaptive Biotechnologies this week:

Positive Sentiment: AAII highlights a sharp intraday rally in ADPT and links the move to the company’s recent quarter-to-quarter momentum, citing earlier-quarter beats in revenue and EPS and strong year-over-year revenue growth as the core catalyst. Why Adaptive Biotechnologies Corporation’s (ADPT) Stock Is Up 10.28%
Positive Sentiment: The Motley Fool coverage notes revenue jumped roughly mid‑50% year-over-year in the most recent period, a headline that supports the bullish narrative on growth and may be driving buying interest; the piece also flags areas investors should watch (guidance, margins, product adoption). Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%
Neutral Sentiment: Executives disclosed that many of the recent stock sales were executed under pre‑arranged Rule 10b5‑1 trading plans, which can reduce concerns of opportunistic timing but still represent share supply hitting the market. SEC Form 4 (Example)
Negative Sentiment: Multiple insider sales by top executives may weigh on sentiment — CEO Chad M. Robins sold blocks on Apr. 6 and Apr. 8 (about 120,595 shares across those filings at prices ~ $14.41–$15.19), and COO Julie Rubinstein sold multiple blocks in early April (roughly 88,000 shares across filings, with trade prices from ~$13.56–$14.83). These transactions reduced each executive’s direct holdings by a few percent. CEO Form 4 COO Form 4

Adaptive Biotechnologies Company Profile

(Get Free Report)

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.